Breast cancer screening for women with a strong familial risk;Le dépistage des cancers du sein chez les femmes à haut risque familial

Bulletin du Cancer

Volumn 92, Issue 10, 2005, Pages 874-884

  Eisinger, François ^a  

^a INSTITUT PAOLI CALMETTES   (France)

Author keywords

BRCA1; BRCA2; Breast cancer; Guidelines; Ovarian cancer; Preventive care; Recommendations

Indexed keywords

BRCA1 PROTEIN;

BREAST CANCER; CANCER PREVENTION; CANCER RISK; CANCER SCREENING; CLINICAL PROTOCOL; FAMILIAL CANCER; FEMALE; FOLLOW UP; HIGH RISK POPULATION; HUMAN; MAMMOGRAPHY; NUCLEAR MAGNETIC RESONANCE IMAGING; ONCOGENE; OVARIECTOMY; OVARY CANCER; REVIEW; RISK BENEFIT ANALYSIS; RISK REDUCTION; SCREENING TEST; ULTRASOUND;

BREAST NEOPLASMS; FAMILY HEALTH; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MAGNETIC RESONANCE IMAGING; MAMMOGRAPHY; RISK; ULTRASONOGRAPHY, MAMMARY;

EID: 27744547708     PISSN: 00074551     EISSN: 17696917     Source Type: Journal    
DOI: None     Document Type: Review

References (77)

1. Juffs HG, Tannock IF. Screening trials are even more difficult than we thought they were. J Natl Cancer lnst 2002; 94: 156-7.
2. Black WC, Haggstrom DA, Welch HG. All-cause mortality in randomized trials of cancer screening. J Natl Cancer Inst 2002; 94: 167-73.
3. Esserman L, Cowley H, Eberle C, Kirkpatrick A, Chang S, Berbaum K, et al. Improving the accuracy of mammography: volume and outcome relationships. J Natl Cancer Inst 2002; 94: 369-75.
4. Thom R, Noel E. Prédire n'est pas expliquer. Paris: Flammarion, 1984.
5. Gerrard M, Gibbons FX, Reis-Bergan M. The effect of risk communication on risk perceptions: the significance of individual differences. J Natl Cancer Inst Monogr 1999; 25: 94-100.
6. Steiner JF. Talking about treatment: the language of populations and the language of individuals. Ann Intern Med 1999; 130: 618-22.
7. Vernon SW. Risk perception and risk communication for cancer screening behaviors: a review. J Natl Cancer Inst Monogr 1999; 25: 101-19.
8. Black D. Corporate tyranny. J Med Ethics 1997; 23: 269-70.
9. Goodman SN. The mammography dilemma: a crisis for evidence-based medicine? Ann Intern Med 2002; 137(5 Part 1): 363-5.
10. Eisinger F, Sobol H. Comments on: Current policies for surveillance and management in women at risk of breast and ovarian cancer: a survey among 16 European family cancer clinics. Eur J Cancer 1999; 35: 859-60.
11. Eisinger F, Bressac B, Castaigne D, Cottu PH, Lansac J, Lefranc JP, et al. Identification et prise en charge des prédispositions héréditaires aux cancers du sein et de l'ovaire (mise à jour 2004). Bull Cancer 2004; 91: 219-37.
12. Wooster R, Weber BL. Breast and ovarian cancer. N Engl J Med 2003; 348: 2339-47.
13. Liaw D, Marsh D, Li J, Dahia P, Wang S, Zheng Z, et al. Germline mutations of PTEN gene in Cowden disease, an inherited breast and thyroide cancer syndrome. Nat Genet 1997; 16: 64-7.
14. Coughlin SS, Khoury MJ, Steinberg KK. BRCA1 and BRCA2 gene mutations and risk of breast cancer. Public health perspectives. Am J Prev Med 1999; 16: 91-8.
15. Tomlinson IP, Houlston RS. Peutz-Jeghers syndrome. J Med Genet 1997; 34: 1007-11.
16. Chenevix-Trench G, Spurdle AB, Gatei M, Kelly H, Marsh A, Chen X, et al. Dominant negative ATM mutations in breast cancer families. J Natl Cancer Inst 2002; 94: 205-15.
17. Thorstenson YR, Roxas A, Kroiss R, Jenkins MA, Yu KM, Bachrich T, et al. Contributions of ATM mutations to familial breast and ovarian cancer. Cancer Res 2003; 63: 3325-33.
18. Baines CJ. Mammography screening: are women really giving informed consent? J Natl Cancer Inst 2003; 95: 1508-11.
19. Berg AO. Mammography screening: are women really giving informed consent? (Counterpoint). J Natl Cancer Inst 2003; 95: 1511-2 (discussion: 1512-3).
20. Baines CJ. Mammography screening: are women really giving informed consent? (Countering the counterpoint). J Natl Cancer Inst 2003; 95: 1512-3.
21. Eisinger F, Guagliardo V, Julian-Reynier C, Moatti J. Dépistage des cancers. In: Guilbert P, Baudier F, Gautier A, eds. Baromètres santé 2000. Paris: CFES, 2001.
22. Eisinger F, Stoppa-Lyonnet D, Longy M, Kerangueven F, Noguchi T, Bailly C, et al. Germ line mutation at BRCA1 affects the histoprognostic grade in hereditary breast cancer. Cancer Res 1996; 56: 471-4.
23. Haehnel P. Dépistage: principes éthiques. Bull Cancer 2001; 88: 407-10.
24. Armstrong D. The rise of surveillance medicine. Social Health Illn 1995; 7: 393-404.
25. Easton DF, Ford D, Bishop DT, and the Breast Cancer Linkage Consortium. Breast and ovarian cancer incidence in BRCA1-mutation carriers. Am J Hum Genet 1995; 56: 265-71.
26. Struewing JP, Hartge P, Wacholder S, Baker SM, Berlin M, McAdams M, et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 1997; 336: 1401-8.
27. Ford D, Easton D, Stratton M, Narod S, Goldgar D, Devilee P, et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. Am J Hum Genet 1998; 62: 676-89.
28. Hopper JL, Southey MC, Dite GS, Jolley DJ, Giles GG, McCredie MR, et al. Population-based estimate of the average age-specific cumulative risk of breast cancer for a defined set of protein-truncating mutations in BRCA1 and BRCA2. Australian Breast Cancer Family Study. Cancer Epidemiol Biomarkers Prev 1999; 8: 741-7.
29. Risch HA, McLaughlin JR, Cole DE, Rosen B, Bradley L, Kwan E, et al. Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am J Hum Genet 2001; 68: 700-10.
30. Antoniou A, Pharoah PD, Narod S, Risch HA, Eyfjord JE, Hopper JL, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 2003; 72: 1117-30.
31. Chappuis P, Stoppa-Lyonnet D, Asselain B, Foulkes W. The natural history of hereditary breast cancer. In: Morrison P, Hodgson S, Naites N, eds. Familial breast and ovarian cancer: genetics, screening and management. Cambridge Press, 2002.
32. Robson M. Breast cancer surveillance in women with hereditary risk due to BRCA1 or BRCA2 mutations. Clin Breast Cancer 2004; 5: 260-8.
33. McIntosh A, Shaw C, Evans G, Turnbull N, Bahar N, Barclay M, et al. Clinical guidelines and evidence review for the classification and care of women at risk of familial breast cancer. National Collaborating Centre for Primary Care/University of Sheffield, 2004.
34. Thomas DB, Gao DL, Ray RM, Wang WW, Allison CJ, Chen FL, et al. Randomized trial of breast self-examination in Shanghai: final results. J Natl Cancer Inst 2002; 94: 1445-57.
35. Brekelmans CT, Seynaeve C, Bartels CC, Tilanus-Linthorst MM, Meijers-Heijboer EJ, Crepin CM, et al. Effectiveness of breast cancer surveillance in BRCA1/2 gene mutation carriers and women with high familial risk. J Clin Oncol 2001; 19: 924-30.
36. Zhang Z, Bast RC, Yu Y, Li J, Sokoll LJ, Rai AJ, et al. Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. Cancer Res 2004; 64: 5882-90.
37. Rui Z, Jian-Guo J, Yuan-Peng T, Hai P, Bing-Gen R. Use of serological proteomic methods to find biomarkers associated with breast cancer. Proteomics 2003; 3: 433-9.
38. Sauter ER, Zhu W, Fan XJ, Wassell RP, Chervoneva I, Du Bois GC. Proteomic analysis of nipple aspirate fluid to detect biologic markers of breast cancer. Br J Cancer 2002; 86: 1440-3.
39. Huo Z, Giger ML, Olopade OI, Wolverton DE, Weber BL, Metz CE, et al. Computerized analysis of digitized mammograms of BRCA1 and BRCA2 gene mutation carriers. Radiology 2002; 225: 519-26.
40. Ziv E, Shepherd J, Smith-Bindman R, Kerlikowske K. Mammographic breast density and family history of breast cancer. J Natl Cancer Inst 2003; 95: 556-8.
41. Boyd NF, Byng JW, Jong RA, Fishell EK, Little LE, Miller AB, et al. Quantitative classification of mammographic densities and breast cancer risk: results from the Canadian National Breast Screening Study. J Natl Cancer Inst 1995; 87: 670-5.
42. Kolb TM, Lichy J, Newhouse JH. Comparison of the performance of screening mammography, physical examination, and breast US and evaluation of factors that influence them: an analysis of 27,825 patient evaluations. Radiology 2002; 225: 165-75.
43. Tilanus-Linthorst M, Verhoog L, Obdeijn IM, Bartels K, Menke-Pluymers M, Eggermont A, et al. A BRCA1/2 mutation, high breast density and prominent pushing margins of a tumor independently contribute to a frequent false-negative mammography. Int J Cancer 2002; 102: 91-5.
44. Tristan H. Imagerie du sein. In: Inserm/FNCLCC, ed. Risques héréditaires de cancers du sein et de l'ovaire. Quelle prise en charge? Paris: Inserm, 1998.
45. Law J. Cancers detected and induced in mammographic screening: new screening schedules and younger women with family history. Br J Radiol 1997; 70: 62-9.
46. Young KC. Radiation doses in the UK trial of breast screening in women aged 40-48 years. Br J Radiol 2002; 75: 362-70.
47. Abbott DW, Thompson ME, Robinson-Benion C, Tomlinson G, Jensen RA, Holt JT. BRCA1 expression restores radiation resistance in BRCA1-defective cancer cells through enhancement of transcription-coupled DNA repair. J Biol Chem 1999; 274: 18808-12.
48. Elmore JG, Barton MB, Moceri VM, Polk S, Arena PJ, Fletcher SW. Ten-year risk of false positive screening mammograms and clinical breast examinations. N Engl J Med 1998; 338: 1089-96.
49. Lehman CD, White E, Peacock S, Drucker MJ, Urban N. Effect of age and breast density on screening mammograms with false-positive findings. Am J Roentgenol 1999; 173: 1651-5.
50. Daly CA, Apthorp L, Field S. Second round cancers: how many were visible on the first round of the UK National Breast Screening Programme, three years earlier? Clin Radiol 1998; 53: 25-8.
51. Anaes. Évaluation clinique de la numérisation en mammographie pour le diagnostic et le dépistage du cancer du sein. Anaes, 2000.
52. Hermann KP, Obenauer S, Marten K, Kehbel S, Fischer U, Grabbe E. Average glandular dose with amorphous silicon full-field digital mammography: clinical results. Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr 2002; 174: 696-9.
53. Noel A, Heid P, Tardivon A, Dilhuydy MH, Haber S, Seradour B. La mammographic de dépistage des femmes ayant une prédisposition héréditaire du cancer du sein. Bull Cancer 2004; 91: 655.
54. Huo Z, Giger ML, Vyborny CJ, Metz CE. Breast cancer: effectiveness of computer-aided diagnosis observer study with independent database of mammograms. Radiology 2002; 224: 560-8.
55. Brem RF, Baum J, Lechner M, Kaplan S, Souders S, Naul LG, et al. Improvement in sensitivity of screening mammography with computer-aided detection: a multiinstitutional trial. Am J Roentgenol 2003; 181: 687-93.
56. Baker JA, Kornguth PJ, Soo MS, Walsh R, Mengoni P. Sonography of solid breast lesions: observer variability of lesion description and assessment. Am J Roentgenol 1999; 172: 1621-5.
57. Kaplan SS. Clinical utility of bilateral whole-breast US in the evaluation of women with dense breast tissue. Radiology 2001; 221: 641-9.
58. Liberman L. Breast cancer screening with MRI: what are the data for patients at high risk? N Engl J Med 2004; 351: 497-500.
59. Kriege M, Brekelmans CT, Boetes C, Besnard PE, Zonderland HM, Obdeijn IM, et al. Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. N Engl J Med 2004; 351: 427-37.
60. Kuhl CK, Schrading S, Leutner CC, Morakkabati N, Trog D, Schmutzler R, et al. Surveillance of "high risk" women with proven or suspected familial (hereditary) breast cancer: first mid-term results of a multimodality clinical screening trial. J Clin Oncol 2003; 21(23 Suppl): 238.
61. Kriege M, Brekelmans CT, Boetes C, Rutgers EJ, Oosterwijk JC, Tollenaar RA, et al. MRI screening for breast cancer in women with high familial and genetic risk: first results of the Dutch MRI screening study (MRISC). J Clin Oncol 2003; 21(23 Suppl): 238.
62. Warner E, Plewes DB, Shumak RS, Catzavelos GC, Di Prospero LS, Yaffe MJ, et al. Comparison of breast magnetic resonance imaging, mammography, and ultrasound for surveillance of women at high risk for hereditary breast cancer. J Clin Oncol 2001; 19: 3524-31.
63. Podo F, Sardanelli F, Canese R, D'Agnolo G, Natali PG, Crecco M, et al. The Italian multi-centre project on evaluation of MRI and other imaging modalities in early detection of breast cancer in subjects at high genetic risk. J Exp Clin Cancer Res 2002; 21(3 Suppl): 115-24.
64. Warner E, Plewes DB, Hill KA, Causer PA, Zubovits JT, Jong RA, et al. Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination. JAMA 2004; 292: 1317-25.
65. Eisinger F, Julian-Reynier C, Sobol H. Biologic characteristics of interval and screen-detected breast cancers. J Natl Cancer Inst 2000; 92: 1533-4.
66. Hartman AR, Daniel BL, Kurian AW, Mills MA, Nowels KW, Dirbas FM, et al. Breast magnetic resonance image screening and ductal lavage in women at high genetic risk for breast carcinoma. Cancer 2004; 100: 479-89.
67. Noel A, Stines J, Heid P, Lisbona A, Verdun FR, Barreau B, et al. Recommandations pour un programme d'assurance de qualité en mammographie numérique. J Radiol 2003; 84: 723-9.
68. Lalloo F, Boggis CR, Evans DG, Shenton A, Threlfall AG, Howell A. Screening by mammography, women with a family history of breast cancer. Eur J Cancer 1998; 34: 937-40.
69. Moller P, Reis MM, Evans G, Vasen H, Haites N, Anderson E, et al. Efficacy of early diagnosis and treatment in women with a family history of breast cancer. European Familial Breast Cancer Collaborative Group. Dis Markers 1999; 15: 179-86.
70. Macmillan RD. Screening women with a family history of breast cancer: results from the British Familial Breast Cancer Group. Eur J Surg Oncol 2000; 26: 149-52.
71. Meijers-Heijboer H, van Geel B, van Putten WL, Henzen-Logmans SC, Seynaeve C, Menke-Pluymers MB, et al. Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 2001; 345: 159-64.
72. Scheuer L, Kauff N, Robson M, Kelly B, Barakat R, Satagopan J, et al. Outcome of preventive surgery and screening for breast and ovarian cancer in BRCA mutation carriers. J Clin Oncol 2002; 20: 1260-8.
73. Komenaka IK, Ditkoff BA, Joseph KA, Russo D, Gorroochurn P, Ward M, et al. The development of interval breast malignancies in patients with BRCA mutations. Cancer 2004; 100: 2079-83.
74. Christiansen CL, Wang F, Barton MB, Kreuter W, Elmore JG, Gelfand AE, et al. Predicting the cumulative risk of false-positive mammograms. J Natl Cancer Inst 2000; 92: 1657-66.
75. Gelfand AE, Wang F. Modelling the cumulative risk for a false-positive under repeated screening events. Stat Med 2000; 19: 1865-79.
76. Meiser B, Butow P, Barratt A, Friedlander M, Kirk J, Gaff C, et al. Breast cancer screening uptake in women at increased risk of developing hereditary breast cancer. Breast Cancer Res Treat 2000; 59: 101-11.
77. Eisinger F, Julian-Reynier C, Chabal F, Luquet C, Moatti J, Sobol H. Acceptable strategies for dealing with hereditary breast/ovarian cancer risk. J Natl Cancer Inst 1997; 89: 731.